Altimmune, Inc.
ALT
$2.91
-$0.02-0.68%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 36.00K | 41.00K | 20.00K | 20.00K | 20.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.00K | 41.00K | 20.00K | 20.00K | 20.00K |
| Cost of Revenue | 66.80M | 66.43M | 67.80M | 72.65M | 76.57M |
| Gross Profit | -66.76M | -66.39M | -67.78M | -72.63M | -76.55M |
| SG&A Expenses | 30.16M | 28.10M | 22.68M | 21.74M | 21.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 96.95M | 94.53M | 90.48M | 94.39M | 98.21M |
| Operating Income | -96.92M | -94.49M | -90.46M | -94.37M | -98.19M |
| Income Before Tax | -91.08M | -88.77M | -84.60M | -88.43M | -90.92M |
| Income Tax Expenses | 0.00 | -681.00K | -681.00K | -681.00K | -681.00K |
| Earnings from Continuing Operations | -91.08 | -88.09 | -83.92 | -87.75 | -90.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -91.08M | -88.09M | -83.92M | -87.75M | -90.24M |
| EBIT | -96.92M | -94.49M | -90.46M | -94.37M | -98.19M |
| EBITDA | -96.81M | -94.38M | -90.34M | -94.24M | -98.03M |
| EPS Basic | -0.94 | -1.02 | -1.07 | -1.18 | -1.25 |
| Normalized Basic EPS | -0.59 | -0.64 | -0.67 | -0.74 | -0.79 |
| EPS Diluted | -0.94 | -1.02 | -1.07 | -1.18 | -1.25 |
| Normalized Diluted EPS | -0.59 | -0.64 | -0.67 | -0.74 | -0.79 |
| Average Basic Shares Outstanding | 395.97M | 347.06M | 317.70M | 299.37M | 288.82M |
| Average Diluted Shares Outstanding | 395.97M | 347.06M | 317.70M | 299.37M | 288.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |